Via EDGAR
August 23, 2016
United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: | Suzanne Hayes, Assistant Director | |
Irene Paik, Staff Attorney | ||
Joseph McCann, Staff Attorney | ||
Re: | OncoSec Medical Incorporated | |
Registration Statement on Form S-3 | ||
Filed August 9, 2016 | ||
File No. 333-213036 |
Dear Ms. Hayes:
This letter is in response to the comments received from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) in the Staff’s comment letter to OncoSec Medical Incorporated (the “Registrant”) dated August 22, 2016, with respect to the registration statement on Form S-3 (File No. 333-213036) initially filed by the Registrant on August 9, 2016 (as amended, the “Registration Statement”). For convenience, in this letter, the text of each of the Staff’s comments appears in boldface type, with the Registrant’s response immediately following each comment in regular type.
Prospectus Cover Page
1. | It appears that you are relying on General Instruction I.B.6 of Form S-3 for this offering. If true, please revise your prospectus cover page to disclose the calculation of the aggregate market value of your outstanding voting and nonvoting common equity and the amount of all securities offered pursuant to General Instruction I.B.6 during the prior 12 calendar month period that ends on, and includes, the date of the prospectus. Refer to Instruction 7 to General Instruction I.B.6. Otherwise, please provide us your analysis demonstrating your eligibility to use Form S-3. |
Response:
In response to the Staff’s comment, the Registrant has revised the prospectus cover page of the Registration Statement to include the requested disclosure.
* * * * * * *
We appreciate your time and attention to this letter and to Amendment No. 1 to the Registration Statement, filed with the Commission on the date hereof. Please direct any comments or inquiries regarding this letter to me, at (855) 662-6732 (telephone) or pdhillon@oncosec.com (e-mail), or to Steven G. Rowles of Morrison & Foerster LLP, at (858) 720-5198 (telephone) or srowles@mofo.com (e-mail).
Very truly yours,
/s/ Punit Dhillon | ||
Name: | Punit Dhillon | |
Title: | President and Chief Executive Officer |
cc: | Richard B. Slansky, Chief Financial Officer |
Steven G. Rowles, Esq., Morrison & Foerster LLP |